Human EBV EA IgA ELISA kit can be used for detecting in-vitro quantitative amounts of human IgA antibodies against Epstein–Barr virus early antigen (EBV EA IgA) using serum or plasma samples. This assay has a minimum analytical sensitivity limit of 1.1 U/ml.
Epstein–Barr virus (EBV) can also be known as human herpesvirus 4 (HHV-4), it belongs to the herpes family of viruses that is very common in humans. The infection with EBV is usually either through genital secretion or by the oral transfer of saliva. EBV-associated infection have in many cases been linked to a high risk of many autoimmune diseases for example systemic lupus erythematosus, dermatomyositis, rheumatoid arthritis, multiple sclerosis and Sjögren’s syndrome. EBV EA appears to be associated to the acute phase of the illness and in most cases drops to undetectable levels after 3-6 months. However, the detection of early antigen (EA) is a good indicator of an active infection. Diagnosing EBV infection are often difficult and challenging due to the fact that the symptoms are very similar to many other illnesses. Blood test and many other laboratory methods (for example ELISA assays) can be helpful to distinguish whether one is susceptible to EBV infection or has had a recent or even a past infection.
EBV EA IGA ELISA KIT CONTENT
All reagents supplied need to be stored at 2 °C – 8 °C, unopened reagents will retain reactivity until expiration date. Do not use reagents beyond this date.
- EBV Early Antigen coated microtiter strips.
- Enzyme Conjugate.
- Sample Diluent.
- Calibrator D (Positive Control).
- Calibrator C (Weak Positive Control).
- Calibrator B (Cut-Off Standard).
- Calibrator A (Negative Control).
- TMB Substrate.
- Washing Buffer (10x).
- Stop Solution.
The minimum detection sensitivity level of IgA antibodies to Epstein–Barr virus early antigen IgA (EBV EA-IgA) using current human EBV EA IgA ELISA kit was 1.1 U/ml. The dynamic range for this assay is 1.0 – 200.0 U/ml.
– EBV EA ELISA: IgA
– Intra-Assay-Precision: 5.8 %.
– Inter-Assay-Precision: 10.2 %.
– Inter-Lot-Precision: 2.2 – 11.8 %.
– Analytical Sensitivity: 1.06 U/mL.
– Recovery: 68 – 120 %.
– Linearity: 71 – 110 %.
– Cross-Reactivity: No cross-reactivity to Herpes, Measles, Mumps and Varicella.
– Interferences: No interferences to bilirubin up to 0.3 mg/mL, hemoglobin up to 8.0 mg/mL and triglycerides up to 5.0 mg/mL.
– Clinical Specificity: 98 %
– Clinical Sensitivity 90 %
- Serum IgA to Epstein-Barr virus early antigen-diffuse identifies Hodgkin’s lymphoma. J Med Virol. (2014) 86 (9): 1621-8. McAllister S.C., et al.
- IgA directed against early antigen of Epstein-Barr virus is no specific marker for the diagnosis of nasopharyngeal carcinoma. J Med Virol. (1994) 43 (3): 222-7. Sigel G., et al.
- Specific IgA antibodies to recombinant early and nuclear antigens of Epstein-Barr virus in nasopharyngeal carcinoma. Clin Otolaryngol Allied Sci. (2001) 26 (4): 334-8. Hsu M.M., et al.
- Detection of IgA antibodies to Epstein-Barr virus-associated antigens by ELISA. J Immunol Methods. (1984) 68 (1-2): 331-9. Dölken G., et al.
- Antibodies to early EBV, CMV, and HHV6 antigens in systemic lupus erythematosus patients. Scand J Rheumatol. (2015) 44 (2): 143-9. Rasmussen N.S., et al.
- Full Name: EBV EA (Early Antigen) IgA ELISA Kit
- Reactivity: Human
- Sample Type: Serum, Plasma
- Sensitivity: 1.1 U/ml